|
|
| (One intermediate revision by the same user not shown) |
| Line 4: |
Line 4: |
|
| |
|
| ==Indications And Usage== | | ==Indications And Usage== |
| 1 INDICATIONS AND USAGE
| | |
| AzaSite® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: | | AzaSite® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: |
| CDC coryneform group G1 | | |
| Haemophilus influenzae | | * CDC coryneform group G1 |
| Staphylococcus aureus | | * [[Haemophilus influenzae]] |
| Streptococcus mitis group | | * [[Staphylococcus aureus]] |
| Streptococcus pneumoniae | | * [[Streptococcus mitis]] group |
| 1
| | * [[Streptococcus pneumoniae]] |
| Efficacy for this organism was studied in fewer than 10 infections. | | |
| 2 DOSAGE AND ADMINISTRATION
| | Efficacy for this organism was studied in fewer than 10 infections.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = |title = AZASITE (AZITHROMYCIN) SOLUTION [INSPIRE PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dc0f75a-1e14-469f-af4f-c668a32f2328 |publisher = | date = | accessdate = }}</ref> |
| The recommended dosage regimen for the treatment of bacterial conjunctivitis is:
| | |
| Instill 1 drop in the affected eye(s) twice daily, eight to twelve hours apart for the first two days and then instill 1 drop in the affected eye(s) once daily for the next five days.
| |
| 3 DOSAGE FORMS AND STRENGTHS
| |
| 2.5 mL of a 1% sterile topical ophthalmic solution.
| |
| 4 CONTRAINDICATIONS
| |
| Hypersensitivity to any component of this product.
| |
| 5 WARNINGS AND PRECAUTIONS
| |
| 5.1 Topical Ophthalmic Use Only
| |
| NOT FOR INJECTION. AzaSite is indicated for topical ophthalmic use only, and should not be administered systemically, injected subconjunctivally, or introduced directly into the anterior chamber of the eye.
| |
| 5.2 Anaphylaxis and Hypersensitivity with Systemic Use of Azithromycin
| |
| In patients receiving systemically administered azithromycin, serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported rarely in patients on azithromycin therapy. Although rare, fatalities have been reported. The potential for anaphylaxis or other hypersensitivity reactions should be considered based on known hypersensitivity to azithromycin when administered systemically.
| |
| 5.3 Growth of Resistant Organisms with Prolonged Use
| |
| As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and where appropriate, fluorescein staining.
| |
| 5.4 Avoidance of Contact Lenses
| |
| Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.
| |
| 6 ADVERSE REACTIONS
| |
| Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with the rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.
| |
| The data described below reflect exposure to AzaSite in 698 patients. The population was between 1 and 87 years old with clinical signs and symptoms of bacterial conjunctivitis. The most frequently reported ocular adverse reaction reported in patients receiving AzaSite was eye irritation. This reaction occurred in approximately 1-2% of patients. Other adverse reactions associated with the use of AzaSite were reported in less than 1% of patients and included ocular reactions (blurred vision, burning, stinging and irritation upon instillation, contact dermatitis, corneal erosion, dry eye, eye pain, itching, ocular discharge, punctate keratitis, visual acuity reduction) and non-ocular reactions (dysgeusia, facial swelling, hives, nasal congestion, periocular swelling, rash, sinusitis, urticaria).
| |
| 8 USE IN SPECIFIC POPULATIONS
| |
| 8.1 Pregnancy
| |
| Pregnancy Category B. Reproduction studies have been performed in rats and mice at doses up to 200 mg/kg/day. The highest dose was associated with moderate maternal toxicity. These doses are estimated to be approximately 5,000 times the maximum human ocular daily dose of 2 mg. In the animal studies, no evidence of harm to the fetus due to azithromycin was found. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, azithromycin should be used during pregnancy only if clearly needed.
| |
| 8.3 Nursing Mothers
| |
| It is not known whether azithromycin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when azithromycin is administered to a nursing woman.
| |
| 8.4 Pediatric Use
| |
| The safety and effectiveness of AzaSite solution in pediatric patients below 1 year of age have not been established. The efficacy of AzaSite in treating bacterial conjunctivitis in pediatric patients one year or older has been demonstrated in controlled clinical trials [see Clinical Studies (14)].
| |
| 8.5 Geriatric Use
| |
| No overall differences in safety or effectiveness have been observed between elderly and younger patients.
| |
| ==References== | | ==References== |
| {{Reflist}} | | {{Reflist}} |